Non-alcoholic fatty liver disease (NAFLD) and Hepatitis B Pathways

Add to CPD Subscribe to page updates Start a discussion

20-30% of our population have non-alcoholic fatty liver disease (NAFLD) and have abnormal LFTs. We will present the new NAFLD pathway and outline which patients need further investigations. There are new guidelines in the management of Hepatitis B, which will be presented, and we will discuss our proposed plans for the monitoring and treatment of Hep B patients in the future.


Speaker

Rob Palmer and Dr Iain Ewing


Broadcast date: November 24th, 2017
Review date: Apr 16th, 2020